HCII-Targeting Nucleic Acid Duplexes for Precise Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene-silencing agents, such as siRNA, antisense RNA, and micro-RNA, face challenges in effectively inhibiting the expression of specific genes like HCII, which are associated with various diseases, and there is a need for more targeted and efficient nucleic acid compounds for therapeutic applications.
Innovation Solution
Development of nucleic acid compounds, including specific duplex regions with complementary strands, designed to inhibit HCII expression by being at least partially complementary to the HCII gene transcript, with sequences differing by 0 or 1 nucleoside, and optionally conjugated with ligand moieties for enhanced delivery and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small organic compounds are used to inhibit protein function, then the therapeutic approach is straightforward, but they cannot effectively silence genes responsible for disease
Solution Approach 1:
The nucleic acid compound is divided into two complementary strands (first strand and second strand) that form a duplex region. Each strand is designed to be complementary to specific portions of the target gene transcript, enabling targeted gene silencing through RNA interference mechanisms while maintaining manageable structural complexity
Solution Approach 2:
The invention uses composite nucleic acid structures combining DNA and RNA elements, with modified nucleosides and potential conjugation to ligand moieties. This composite approach enhances stability and targeting capability while achieving effective gene silencing
2Reliability
If nucleic acid compounds are designed to be highly complementary to target gene transcripts, then gene silencing efficacy is improved, but specificity and off-target effects become critical concerns
Solution Approach 1:
The nucleic acid compound features localized regions of high complementarity (17-23 contiguous nucleosides) within the duplex region, rather than uniform complementarity throughout. This localized high-quality matching to the target sequence enhances specificity while the remaining portions provide structural stability without contributing to off-target binding
Solution Approach 2:
The invention uses partial complementarity (allowing 0-1 mismatches in 17-23 nucleotide regions) rather than requiring perfect matching across the entire nucleic acid sequence. This partial action approach maintains high specificity for the target gene while reducing the risk of off-target effects compared to excessive complementarity
3Adaptability or versatility
If nucleic acid compounds are administered systemically, then broad therapeutic coverage is achieved, but delivery efficiency and stability in biological systems decrease
Solution Approach 1:
The invention introduces ligand moieties (such as GalNAc conjugates) as intermediaries that facilitate the delivery of nucleic acid compounds to specific target cells, particularly hepatocytes. These ligands act as mediators between the nucleic acid therapeutic and the cellular uptake machinery, significantly improving delivery efficiency while maintaining systemic administration capability
Solution Approach 2:
The nucleic acid compound undergoes chemical modifications including 2'-O-methyl and 2'-fluoro substitutions on nucleosides, which change the physical and chemical parameters of the molecule. These parameter changes enhance stability against nucleases, improve cellular uptake, and maintain RNAi activity, thereby improving delivery efficiency and therapeutic reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The designed nucleic acid compounds effectively inhibit HCII expression, providing a targeted therapeutic approach for diseases related to HCII, with potential applications in treating disorders of haemostasis such as haemophilia.
Implementation Method 1
a duplex region that comprises a first strand and a second strand that is at least partially complementary to the first strand, wherein said first strand is: (i) at least partially complementary to a portion of RNA transcribed from the HCII gene
Data Source
AI summary
The present invention provides novel nucleic acid compound suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.